Foley is pleased to sponsor the 14th Calbio Summit. This annual conference brings together Southern California’s life science community to network and discuss pertinent issues impacting the region and the industry.
R. Michael Scarano, Jr., partner and co-chair of the Life Sciences Industry Team, will moderate a conference session entitled, The Evolving Reimbursement Environment: What Every Life Sciences Company Should Know.
Even the most innovative and effective product will face commercial failure if adequate reimbursement is not available. Recent changes in Medicare law and the cumbersome policies of both government and private payers pose new challenges for biotechnology, device and pharmaceutical companies, requiring proactive planning as early as possible in the product development process. A panel of experts will provide their insights into how companies can integrate reimbursement planning into an overall regulatory strategy, including how to design clinical trials with an eye towards satisfying both CMS and FDA requirements. The panel will also address issues such as:
- How to build the financial impact of reimbursement policies into market models
- How Medicare factors cost-effectiveness into coverage decisions
- How Medicare Part D has affected reimbursement for drugs
- How the new Congress is likely to shape federal payment policies
Jayson Slotnik, Esq., M.P.H.
Director, Medicare Reimbursement and Economic Policy
Biotechnology Industry Organization (BIO)
Randel E. Richner, B.S.N., M.P.H.
President, Neocure Bioeconomic Strategies (formerly Vice President, Global Government Affairs for Boston Scientific Corporation).